Tragen Pharmaceuticals (formerly dba Immunogenex, Inc.) had been developing a family of potent biotherapeutics for the treatment of disease. An immunology company focused on cancer and autoimmune diseases, the core of Tragen's proprietary technology werer ecombinant forms of the tumor necrosis factor (TNF) family of molecules. With the expertise of the firm's principals being in gene delivery systems, the effort organzied around creating an effective and sustainable approach for treating disease
